公开(公告)号：US20220313902A1

公开(公告)日：2022-10-06

申请号：US17842564

申请日：2022-06-16

申请人： Zealand Pharma A/S

发明人： Robert R. Gonnelli ,  Steven F. Levesque ,  David Lipson ,  Peter F. Marshall

IPC分类号： A61M5/155 ,  A61M5/145 ,  A61M5/168 ,  A61M5/142 ,  A61M5/158

摘要： Embodiments of this invention relate to a fluid delivery device. The fluid delivery device comprises a fluid reservoir for containing a fluid, a first drive mechanism configured to remove a predetermined amount of the fluid from the fluid reservoir when the first drive mechanism is actuated, a needle, a septum and a housing having an orifice. Also disclosed is a method for dispensing a fluid from a fluid delivery device into a patient.

公开(公告)号：US20220202704A1

公开(公告)日：2022-06-30

申请号：US17617675

申请日：2020-06-12

申请人： Zealand Pharma A/S

发明人： Lise Giehm ,  Alistair Vincent Gordon Edwards

IPC分类号： A61K9/00 ,  A61K47/26 ,  A61K47/02 ,  A61K47/54

摘要： The present invention relates to pharmaceutical compositions suitable for parenteral administration in human subjects. In particular, the present invention relates to isotonic pharmaceutical compositions for parenteral administration.

公开(公告)号：USD955566S1

公开(公告)日：2022-06-21

申请号：US29740199

申请日：2020-07-01

申请人： Zealand Pharma A/S

设计人： Christopher Gregory ,  Geoffrey Jenkins ,  Matthew Johnson

公开(公告)号：US11324799B2

公开(公告)日：2022-05-10

申请号：US16609963

申请日：2018-05-04

申请人： ZEALAND PHARMA A/S ,  BOSTON MEDICAL CENTER CORPORATION

发明人： Bjarne Due Larsen ,  Ulrik Mouritzen ,  Dongjoon Kim ,  Sayon Roy

IPC分类号： A61K38/08 ,  A61P3/10 ,  A61K31/40

摘要： The use of gap junction intercellular communication (GJIC) modulators in the treatment or prevention of diabetic eye disease is disclosed, and more particularly to their use for the treatment or prevention of early stage diabetic retinopathy and diabetic macular edema by inhibiting apoptosis of retinal endothelial cells and inhibiting pericyte loss.

公开(公告)号：US20220016334A1

公开(公告)日：2022-01-20

申请号：US17491949

申请日：2021-10-01

申请人： Zealand Pharma A/S

发明人： Robert R. GONNELLI ,  Steven F. LEVESQUE ,  Ronald V. NARDI

IPC分类号： A61M5/14 ,  A61M5/145 ,  A61M5/168 ,  A61M5/32

摘要： A fluid delivery device for administering a first medicament and a second medicament includes a first fluid reservoir configured to contain the first medicament and a second fluid reservoir configured to contain the second medicament. The fluid delivery device may include one or more basal drive mechanisms to provide a basal delivery of one or more of the first and second medicaments. The fluid delivery device may further include one or more bolus drive mechanisms to provide a bolus delivery of one or more of the first and second medicaments.

公开(公告)号：US20210363213A1

公开(公告)日：2021-11-25

申请号：US17388328

申请日：2021-07-29

申请人： Zealand Pharma A/S

发明人： Rasmus JUST ,  Ditte RIBER ,  Anne Pernille Tofteng SHELTON ,  Torben ØSTERLUND ,  Kate HANSEN ,  Lene JESSEN

IPC分类号： C07K14/605

摘要： The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.

公开(公告)号：US20210346468A1

公开(公告)日：2021-11-11

申请号：US17381373

申请日：2021-07-21

申请人： Zealand Pharma A/S

发明人： Jesper Mosolff MATHIESEN ,  Jesper Skodborg VILLADSEN ,  Lise GIEHM ,  Henrik Kofoed MUNCH ,  Dieter Wolfgang HAMPRECHT ,  Alexander HEIM-RIETHER ,  Giacomo FOSSATI

IPC分类号： A61K38/22 ,  C07K14/575

摘要： The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

公开(公告)号：USD935604S1

公开(公告)日：2021-11-09

申请号：US29771869

申请日：2021-02-25

申请人： Zealand Pharma A/S

设计人： Christopher Gregory ,  Geoffrey Jenkins ,  Matthew Johnson

公开(公告)号：US11130793B2

公开(公告)日：2021-09-28

申请号：US16466930

申请日：2017-12-11

申请人： Zealand Pharma A/S

发明人： Bjarne Due Larsen ,  Lise Giehm ,  Alistair Vincent Gordon Edwards

IPC分类号： C07K14/605 ,  A61P3/10 ,  A61P1/00 ,  A61K38/00

摘要： The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

公开(公告)号：US11111285B2

公开(公告)日：2021-09-07

申请号：US16151603

申请日：2018-10-04

申请人： Zealand Pharma A/S

发明人： Rasmus Just ,  Ditte Riber ,  Anne Pernille Tofteng Shelton ,  Torben Østerlund ,  Kate Hansen ,  Lene Jessen

IPC分类号： C07K14/605 ,  A61K38/00 ,  A61P19/08 ,  A61P19/10 ,  A61P29/00 ,  A61P3/00 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

摘要： The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.